期刊
CHINESE HERBAL MEDICINES
卷 14, 期 2, 页码 273-282出版社
ELSEVIER SINGAPORE PTE LTD
DOI: 10.1016/j.chmed.2022.03.002
关键词
network pharmacology; nonalcoholic fatty liver disease; Three Flower Tea
资金
- National Natural Science Foundation of China [81903878]
- Natural Science Foundation of Shandong Province, China [ZR2019BH049]
- Major Science and Technology Innovation Project of Shandong Province [2019JZZY020611-04]
This study investigated the therapeutic effect and mechanisms of the traditional Chinese medicine Three Flower Tea (TFT) on nonalcoholic fatty liver disease (NAFLD) using network pharmacology and animal experiments. The results demonstrated that TFT can prevent and treat NAFLD by targeting multiple pathways, including lipid accumulation, antioxidation, insulin sensitivity, and inflammation.
Objective: Nonalcoholic fatty liver disease (NAFLD) has become a common chronic liver disease that is harmful to human health. Moreover, there is currently no FDA-approved first-line drug for the treatment of nonalcoholic steatohepatitis (NASH) or NAFLD. Traditional Chinese medicine (TCM) is widely used to ameliorate liver diseases, such as the traditional ancient recipe called Three Flower Tea (TFT), which consists of double rose (Rosa rugosa), white chrysanthemum (Chrysanthemum morifolium), and Daidaihua (Citrus aurantium). However, the mechanisms of the action of TFT are not clear. Therefore, this study aimed to elucidate the mechanisms of TFT against NAFLD in high-fat diet (HFD)-induced rats. Methods: This study utilized bioinformatics and network pharmacology to establish the active and potential ingredient-target networks of TFT. Furthermore, a protein-protein interaction (PPI) network was constructed, and enrichment analysis was performed to determine the key targets of TFT against NAFLD. Furthermore, an animal experiment was conducted to evaluate the therapeutic effect and confirm the key targets of TFT against NAFLD. Results: A total of 576 NAFLD-related genes were searched in GeneCards, and under the screening criteria of oral bioavailability (OB) > 30% and drug-likeness (DL) > 0.18, a total of 19 active ingredients and 210 targets were identified in TFT. Network pharmacology analysis suggested that 55 matching targets in PPIs were closely associated with roles for NAFLD treatment. Through the evaluation of network topology parameters, four key central genes, PPARc, SREBP, AKT, and RELA, were identified. Furthermore, animal experiments indicated that TFT could reduce plasma lipid profiles, hepatic lipid profiles and hepatic fat accumulation, improve liver function, suppress inflammatory factors, and reduce oxidative stress. Through immunoblotting and immunofluorescence analysis, PPARc, SREBP, AKT, and RELA were confirmed as targets of TFT in HFD-induced rats. Conclusion: In summary, our results indicate that TFT can prevent and treat NAFLD via multiple targets, including lipid accumulation, antioxidation, insulin sensitivity, and inflammation. (C 2022 Tianjin Press of Chinese Herbal Medicines. Published by ELSEVIER B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据